J Korean Diabetes.  2012 Dec;13(4):191-195. 10.4093/jkd.2012.13.4.191.

Evaluation of Cardiovascular Disease in Patients with Diabetes Mellitus Using Myocardial Perfusion SPECT

• Chung HW

• KMID: 2173954
• DOI: http://doi.org/10.4093/jkd.2012.13.4.191

Abstract

The number of patients with diabetes mellitus increases every year. Compared with the nondiabetic population, diabetic patients have an increased risk of developing cardiovascular disease and an increased risk for death from myocardial infarction or congestive heart failure. In diabetic patients, compared with people without diabetes, coronary artery disease is often silent, more advanced at diagnosis, and associated with an unfavorable prognosis. To maximize the effect of appropriate treatment, it is important to stratify patients according to their risk of future clinical events as early as possible. Commonly used noninvasive tests in coronary artery disease include exercise ECG, stress echocardiography, coronary CT and MRI, and stress myocardial perfusion SPECT. The generally used radioisotopes for myocardial perfusion SPECT are 201Tl and technetium-based agents such as 99mTc-MIBI and 99mTc-tetrofosmin. Stress myocardial perfusion SPECT provides information on perfusion and function including wall motion, ejection fraction, and myocardial viability. Also, the hemodynamic significance of coronary artery stenosis can be assessed. Stress myocardial perfusion SPECT provides quantifiable data and identifies patients with diabetes who are at low and high risk for future adverse cardiovascular events. These risk stratification data are useful in planning appropriate treatment strategies for patients with diabetes.

Keyword

Myocardial perfusion SPECT; Coronary artery disease; Diabetes mellitus

MeSH Terms

Cardiovascular Diseases
Coronary Artery Disease
Coronary Stenosis
Diabetes Mellitus
Echocardiography, Stress
Electrocardiography
Heart Failure
Hemodynamics
Humans
Myocardial Infarction
Organophosphorus Compounds
Organotechnetium Compounds
Perfusion
Prognosis
Radioisotopes
Tomography, Emission-Computed, Single-Photon
Organophosphorus Compounds
Organotechnetium Compounds
Radioisotopes

Reference

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011. 94:311–321.

2. Diabetes mellitus: a major risk factor for cardiovascular disease. A Joint Editorial Statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999. 100:1132–1133.

3. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol. 1997. 79:134–139.

4. Vanzetto G, Halimi S, Hammoud T, Fagret D, Benhamou PY, Cordonnier D, Denis B, Machecourt J. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care. 1999. 22:19–26.

5. Weich HF, Strauss HW, Pitt B. The extraction of thal l ium-201 by the myocardium. Circulation. 1977. 56:188–191.

6. Strauss HW, Harrison K, Langan JK, Lebowitz E, Pitt B. Thallium-201 for myocardial imaging. Relation of thallium-201 to regional myocardial perfusion. Circulation. 1975. 51:641–645.

7. Mousa SA, Cooney JM, Williams SJ. Relationship between regional myocardial blood flow and the distribution of 99mTc-sestamibi in the presence of total coronary artery occlusion. Am Heart J. 1990. 119:842–847.

8. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med. 1994. 35:510–515.

9. Glover DK, Ruiz M, Yang JY, Smith WH, Watson DD, Beller GA. Myocardial 99mTc-tetrofosmin uptake during adenosine-induced vasodilatation with either a critical or mild coronary stenosis: comparison with 201Tl and regional myocardial blood flow. Circulation. 1997. 96:2332–2338.

10. Hamada S, Nakamura S, Sugiura T, Nishiue T, Watanabe J, Hatada K, Miyoshi H, Baden M, Iwasaka T. Accuracy of technetium-99m tetrofosmin myocardial perfusion imaging in the detection of spontaneous recanalization in patients with acute anterior myocardial infarction. Eur J Nucl Med. 2001. 28:326–333.

11. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation. 1996. 93:905–914.

12. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Kinoshita M, Kumano S. Comparison of adenosine triphosphate and dipyridamole in diagnosis by thallium-201 myocardial scintigraphy. J Nucl Med. 1997. 38:577–581.

13. Beller GA. Myocardial perfusion imaging with thallium-201. J Nucl Med. 1994. 35:674–680.

14. Bokhari S, Ficaro EP, McCallister BD Jr. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol. 2007. 14:415–416.

15. Heller GV, Brown KA, Landin RJ, Haber SB. Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS). Am Heart J. 1997. 134:105–111.

16. Travain MI, Wexler JP. Pharmacological stress testing. Semin Nucl Med. 1999. 29:298–318.

17. Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol. 1997. 29:69–77.

18. Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, Friedman JD, Zellweger MJ, Berman DS. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation. 1999. 100:1035–1042.

19. Hachamovitch R, Shaw LJ, Berman DS. The ongoing evaluation of risk stratification using myocardial perfusion imaging in patients with known or suspected coronary disease. ACC Curr J Rev. 1999. 8:66–71.

20. Iskander S, Iskandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol. 1998. 32:57–62.

21. Paillole C, Ruiz J, Juliard JM, Leblanc H, Gourgon R, Passa P. Detection of coronary artery disease in diabetic patients. Diabetologia. 1995. 38:726–731.

22. Boudreau RJ, Strony JT, duCret RP, Kuni CC, Wang Y, Wilson RF, Schwartz JS, Castaneda-Zuniga WR. Perfusion thallium imaging of type I diabetes patients with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology. 1990. 175:103–105.

23. Bell DS, Yumuk VD. Low incidence of false-positive exercise thallium 201 scintigraphy in a diabetic population. Diabetes Care. 1996. 19:185–186.

24. Kang X, Berman DS, Lewin H, Miranda R, Erel J, Friedman JD, Amanullah AM. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J. 1999. 137:949–957.

25. Kang X, Berman DS, Lewin HC, Cohen I, Friedman JD, Germano G, Hachamovitch R, Shaw LJ. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J. 1999. 138(6 Pt 1):1025–1032.

26. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, Borges-Neto S, Berman DS, Waters DD, Heller GV. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation. 2002. 105:32–40.

27. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008. 117:1283–1291.

28. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009. 360:213–224.

29. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010. 56:177–184.

30. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van't Veer M, Pijls NH. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010. 55:2816–2821.

31. Schinkel AF, Bax JJ, Geleijnse ML, Boersma E, Elhendy A, Roelandt JR, Poldermans D. Noninvasive evaluation of ischaemic heart disease: myocardial perfusion imaging or stress echocardiography? Eur Heart J. 2003. 24:789–800.

32. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm SD, Marquardt M, Johansson L. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008. 29:480–489.

33. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003. 361:374–379.